Finance Watch: 2021 Is Now Two Away From 100 Biopharma IPOs
Three Health Care-Focused SPACs Also Went Public
Executive Summary
Public Company Edition: Entrada’s initial public offering grossed $181.5m while Aura raised $75.6m and Biofrontera brought in $18m. Also, AnaptysBio received $250m in Jemperli royalty deal and 4D Molecular Therapeutics grossed $118.8m in a follow-on offering.
You may also be interested in...
BMS Is Latest To Join Synthetic Lethality Bandwagon With Volastra Deal
Deal Snapshot: The drug maker is betting $30m up front and up to $1.1bn in milestone fees for an increasingly popular approach to oncology drug development.
Frazier Sees Opportunity For New $987m Fund Despite Financial Market Turmoil
Frazier Life Sciences managing partner James Topper described how the firm will use its 11th fund to launch new companies, support growing firms and take advantage of public market opportunities.
Pipeline Watch: Phase III Readouts In Breast And Liver Cancer Plus COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.